![]() |
|
|
Vol. 60, Issue 1, 209-216, July 2001
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (L.F., N.P., E.T.M.); Centre du Médicament, Institut National de la Santé et de la Recherche Médicale U525, Faculty of Pharmacy of Nancy, Nancy, France (L.F.); and Department of Pharmacology and Toxicology, University of Texas Medical Branch at Galveston, Galveston, Texas (J.R.H.)
| |
Abstract |
|---|
|
|
|---|
There are conflicting reports about the role of nitric oxide in the down-regulation of cytochrome P450 that occurs when animals or cultured hepatocytes are exposed to inflammatory stimuli. Here, we investigated the participation of NO in the down-regulation of CYP2B1 by bacterial endotoxin (LPS) in rat hepatocytes cultured on Matrigel. LPS caused the down-regulation of CYP2B1 mRNA to 20% of control values within 12 h of treatment, and this was not reversed by concentrations of NO synthase inhibitors that completely blocked NO production. LPS was several orders of magnitude more potent in the down-regulation of CYP2B1 mRNA than in induction of NO production. In contrast, concentrations of LPS in the 1 to 100 ng/ml range induced NO production and produced a rapid down-regulation of CYP2B1 protein to 30% and <5% of control at 6 and 24 h, respectively, that could be completely prevented both by inhibitors of NO synthase and by LY83583, which prevents NO synthase-2 induction. The blockade of CYP2B1 down-regulation by NO synthase inhibitors was reversed by arginine, and the NO donors S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine mimicked CYP2B1 protein suppression. Taken together, these experiments demonstrate two independent mechanisms of CYP2B1 down-regulation by LPS: a rapid, NO-dependent suppression of the protein occurring at high concentrations of LPS and a slower, NO-independent pretranslational suppression occurring at low concentrations of LPS.
| |
Introduction |
|---|
|
|
|---|
Exposure
of animals or cultured hepatocytes to inflammatory stimuli or cytokines
causes decreases in total microsomal cytochrome P450 (P450),
P450-catalyzed enzyme activities, and levels of P450 proteins and mRNAs
in the hepatocyte (Morgan, 1997
). These conditions also induce hepatic
inducible nitric-oxide synthase [NOS2 (or iNOS)] activity and
production of NO in both hepatocytes and Kupffer cells (Billiar et al.,
1992
). Because NO reacts with hemoproteins and is produced in the same
cells in which P450 enzymes become inhibited or down-regulated, it has
been hypothesized that the stimulation of NO production in the liver
during inflammatory responses causes the observed changes in P450
activities and expression. As will be discerned from the following
discussion, this has been a topic of extensive study and has yielded
conflicting results.
Nitric oxide, peroxynitrite, and NO donors are capable of inhibiting
the catalytic activities of hepatic microsomal P450s (Wink et al.,
1993
; Kim et al., 1995
; Minamiyama et al., 1997
) purified P450s
(Roberts et al., 1998
), and CYP8A1 (prostacyclin synthase) (Zou et al.,
1998
). This occurs by at least three mechanisms: reversible ligation of
NO to (primarily ferrous) P450 heme (Wink et al., 1993
), oxidation of
P450 protein thiols (Takemura et al., 1999
); and nitrosylation of
specific tyrosine residues on the enzyme (Roberts et al., 1998
).
Inhibitors of NOS have been demonstrated to block or attenuate
decreases in spectrally measurable microsomal P450 and P450-dependent
catalytic activities associated with NOS2 induction by inflammatory
stimuli in cultured rat (Stadler et al., 1994
; Osawa et al., 1995
) and
human (Donato et al., 1997
) hepatocytes, rat mesangial cells (Zou et
al., 1998
), and whole animals (Khatsenko et al., 1993
; Muller et al.,
1996
; Khatsenko and Kikkawa, 1997
; Takemura et al., 1999
).
In contrast to its well-documented effects on P450 catalytic activities
and spectral properties, the role of NO in the down-regulation of P450
mRNAs and proteins during an inflammatory response is more
controversial. Studies in different laboratories using NOS inhibitors
have produced conflicting results. For instance, Khatsenko and Kikkawa
(1997)
reported that NOS inhibitors could protect CYP2C11 and CYP3A2
protein and mRNAs from suppression by bacterial lipopolysaccharide
(LPS) treatment of Sprague-Dawley rats. In contrast, we (Sewer and
Morgan, 1998
) and others (Takemura et al., 1999
) found that the
decreases in expression of these P450s were not affected by inhibition
of NOS activity. Moreover, we found that LPS treatment suppresses the
expression of CYP2C and 3A mRNA and proteins equally well in wild-type
and NOS2-null mouse livers (Sewer et al., 1998
), indicating that the
suppression is NO-independent. Similarly conflicting results have been
obtained from studies on the effects of NOS inhibitors on P450
down-regulation in cultured hepatocytes (Stadler et al., 1994
; Carlson
and Billings, 1996
; Monshouwer et al., 1996
). For example, our
laboratory found no effect of NOS inhibition on the down-regulation of
CYP2C11 mRNA and protein by LPS or interleukin (IL)-1 (Sewer and
Morgan, 1997
). In contrast, it was reported that NOS inhibition could block down-regulation in hepatocytes of CYP1A1 mRNA and protein, and of
CYP2B, -2C11, -1A2, and -3A2 proteins (Carlson and Billings, 1996
),
caused by cytokine combinations.
Some of the most convincing evidence for participation of NO in
down-regulation of P450 mRNAs and proteins has been obtained with
phenobarbital (PB)-inducible CYP2B enzymes. Administration of
N
-nitro-L-arginine methyl
ester to rats treated with PB and LPS blocked the suppression of
CYP2B1/2 activity, mRNA and protein (Khatsenko et al., 1993
, 1997
).
Inhibitors of NOS also blocked the suppression of CYP2B1/2 proteins by
a cytokine combination in short-term cultures of rat hepatocytes
(Carlson and Billings, 1996
), although the regulation of CYP2B1/2 mRNAs
in this system was not reported. However, Milosevic et al. (1999)
reported recently that LPS caused suppression of CYP2B1 mRNA and
protein only when hepatocytes were cocultured with Kupffer cells. This
down-regulation was dependent on tumor necrosis factor-
(TNF
)
release from the Kupffer cells and independent of NO production
(Milosevic et al., 1999
).
In the present study, we have used rat hepatocytes cultured on Matrigel to investigate the participation of endogenous NO in the down-regulation of CYP2B mRNAs and proteins by LPS and IL-1 in hepatocytes. Our results show for the first time that the down-regulation of a single P450 in hepatocytes in response to an inflammatory agent can occur by two independent mechanisms in a concentration-dependent manner. Down-regulation of CYP2B1 mRNA in this system occurs at low LPS concentrations and is independent of NO, whereas the suppression of CYP2B proteins occurs at high LPS concentrations and at early time points, and is caused by NO production.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Male Fischer 344 rats (175-200 g) from Harlan
Sprague-Dawley (Indianapolis, IN) or Charles River Laboratories
(Wilmington, MA) were used for hepatocyte isolation. Cell culture
medium (Waymouth's MB 752/1), insulin, antibiotics, and murine
recombinant IL-1
were purchased from Invitrogen (Carlsbad,
CA). Chromatographically purified Escherichia coli LPS,
serotype 0127:B8, N-monomethyl-L-arginine (NMA), aminoguanidine (AG), sulfanilamide,
N-(1-naphthyl)ethylenediamine, glutathione, resorufin,
pentoxyresorufin, NADPH:nitrate reductase, and Type IV collagenase were
purchased from Sigma Chemical Co. (St. Louis, MO).
S-nitroso-N-acetylpenicillamine (SNAP) and
S-nitrosoglutathione (GSNO) were obtained from BIOMOL
Research Laboratories Inc (Plymouth Meeting, PA). LY83583 was from
Calbiochem (La Jolla, CA). Horseradish peroxidase-coupled goat
anti-rabbit IgG was purchased from Jackson Immunoresearch Laboratories
(West Grove, PA). The plasmid pAstNOS-4, containing the 3' end of the
NOS2 cDNA, was a generous gift from Dr. D.L. Feinstein (Cornell
University, Ithaca, NY).
Hepatocyte Isolation, Culture, and Treatments.
Matrigel,
prepared according to the method of Schuetz et al. (1988)
, was diluted
to 6 to 7 mg/ml with Waymouth's medium, applied to 60-mm plastic
culture dishes (Nunc; Fisher Scientific, Pittsburgh, PA), and allowed
to gel at 37°C for 1 to 2 h. Isolation of rat hepatocytes was
performed by in situ collagenase perfusion as described previously
(Sewer and Morgan, 1997
). Cells (3.0 × 106/60 mm plate) were plated in 3 ml of
Waymouth's medium containing 0.15 µM insulin. Cultures were
maintained for 5 to 7 days at 37°C in 5% CO2
atmosphere. The medium was replaced every 48 h, commencing 4 h after plating.
Isolation of Total RNA and Slot-Blot Assays.
Total
hepatocyte RNA was prepared by the acid phenol extraction method
(Chomczynski and Sacchi, 1987
). Relative levels of CYP2B1 and NOS2
mRNAs in the samples were measured by a slot blot assay using the
CYP2B1-specific oligonucleotide described by Omiecinski et al. (1985)
or a cDNA to the 3' end of the NOS2 mRNA (Galea et al.,
1994
), respectively. Total RNA was denatured using formaldehyde and loaded onto Nytran filters (Schleicher & Schuell, Keene, NH) in the slot blot manifold. The RNA was immobilized by both
UV irradiation and baking at 80°C. The CYP2B1 oligonucleotide probe
was labeled using T4 polynucleotide kinase and
[
-32P]ATP and was hybridized with the
immobilized RNA overnight at 45°C in 1× standard
saline/phosphate/EDTA buffer (0.18 M NaCl and 1 mM EDTA in 10 mM sodium
phosphate buffer, pH 7.7) containing 5× Denhardt's solution, 0.5%
SDS, 0.1 mg/ml yeast tRNA, and 1 mM EDTA. Blots were washed twice for
30 min with 1× SSC (0.15 M NaCl in 15 mM sodium citrate, pH 7.0)
containing 0.5% SDS, and twice for 30 min with 0.2× SSC, 1.0% SDS at
room temperature. The final wash was for 30 min with 0.1× SSC, 0.5%
SDS at 38°C. The NOS2 cDNA was labeled using the Megaprime labeling
kit (Amersham Pharmacia Biotech, Piscataway, NJ) and
[
-32P]dCTP. Hybridization and washing
conditions for this probe have been described previously (Sewer et al.,
1997
). Bound 32P-labeled probes were detected and
quantified on a PhosphorImager (Molecular Dynamics, Santa Clara, CA).
All slot-blot results were normalized to the content of
poly(A+) RNA, measured by probing slot blots with
an oligo(dT)30 probe (Sewer and Morgan, 1997
).
Microsomal Protein Isolation, Western Blotting, and Enzyme
Assays.
Microsomes were isolated by differential
ultracentrifugation, using a Beckman TLK tabletop ultracentrifuge
(Beckman Coulter, Inc., Fullerton, CA) as described previously (Iber et
al., 1997
). Microsomal protein concentration was determined by the
method of Lowry et al. (1951)
using bovine serum albumin as a standard. Relative levels of CYP2B1 protein in the microsomes were measured by
Western blotting, under conditions of linearity with respect to the
amount of protein applied. Blots were incubated for 1 h at room
temperature in phosphate-buffered saline containing a 1:12,500 dilution
of rabbit CYB2B1 antiserum (Duignan et al., 1987
). After washing three
times with phosphate-buffered saline, they were incubated for 1 h
with a 1:2000 dilution of horseradish peroxidase-coupled goat
anti-rabbit IgG. Bound antibody complexes were measured by enhanced
chemiluminescence detection (ECL; Amersham Pharmacia Biotech), followed
by autoradiography and video densitometry (Lynx system; Applied
Imaging, Santa Clara, CA).
Analysis of Nitrite and Nitrate Concentration.
The stable
products of NO synthesis, nitrate and nitrite (NOx), were measured in
the culture media using a colorimetric method based on the Griess
reaction as described previously (Sewer and Morgan, 1997
). Nitrate was
reduced to nitrite with NADPH:nitrate reductase (98% conversion).
Nitrite concentrations in the reduced samples were measured at 540 nm
with a Thermomax microplate reader (Molecular Devices) using the Griess
reagent and a sodium nitrite standard curve.
Statistical Analysis. One-way analysis of variance and the Neumann-Keuls test were used to determine differences among treatment groups. Data from slot-blot and Western blot assays were expressed in arbitrary units or as a percentage of the mean of an appropriate control group in each experiment.
| |
Results |
|---|
|
|
|---|
In initial experiments, we optimized the conditions for maximal
induction and stable expression of CYP2B1 mRNA in the presence of PB.
As reported by others using different culture conditions (Sidhu and
Omiecinski, 1995
), the concentration dependence of induction over the
period of 0 to 72 h in our cultures was biphasic (not shown), and
the optimal concentration of 1 mM PB was selected for all other experiments.
Concentration-Dependent Suppression of CYP2B1 by LPS
Treatment.
Treatment of the cells with LPS for 24 h caused a
suppression of PB-induced CYP2B1 mRNA (Figs.
1A and 2A),
and protein expression (Figs. 1B and 2B). However, LPS was more potent
in suppression of CYP2B1 mRNA (EC50 < 1 pg/ml)
than in induction of NO production (EC50 >10
ng/ml) (Fig. 2A). On the other hand, LPS treatment suppressed CYP2B
protein expression by LPS with potency similar to that of NOS2
induction (Fig. 2B). Western blots of microsomes from PB-treated hepatocyte yielded one major band and one minor band with a slightly lower mobility. These bands had identical mobilities to purified CYP2B1
and 2B2, respectively, and were sufficiently resolved to be measured
independently by video densitometry (data not shown). Although these
bands tended to be affected similarly by the various treatments, only
the CYP2B1 band was measured in these studies. Treatment of cells for
6 h or 24 h with 10
5 or
10
10 g/ml LPS or 5 ng/ml IL-1 had no effect on
the expression of glyceraldehyde 3-phosphate dehydrogenase mRNA
measured by Northern blotting (data not shown).
|
|
NO-Independent Suppression of CYP2B1 mRNA by LPS.
The earliest
detectable suppression of CYP2B1 mRNA by either high or low
concentrations of LPS occurred 12 h after addition of LPS to the
medium (Fig. 3). CYP2B1 mRNA levels
remained low 24 h (Fig. 2) and 48 h (Fig. 3) after treatment.
Interestingly, low concentrations of LPS produced a transient induction
of CYP2B1 mRNA 6 h (but not 3 h) after addition to the medium
(Fig. 3). Suppression of CYP2B1 mRNA was independent of NO production
by the hepatocytes, because concentrations of the NOS inhibitor NMA that completely blocked NO production failed to affect down-regulation of CYP2B1 mRNA by LPS (Fig. 4). A similar
lack of effect of 300 µM AG, which also blocked NO production
stimulated by LPS, on CYP2B1 down-regulation was observed (not shown).
|
|
NOS Inhibitors Block Suppression of CYP2B1 Protein Expression by
High Concentrations of LPS.
High concentrations of LPS suppressed
CYP2B1 protein levels and PROD activities as early as 8 h after
addition of LPS to the cultures (Fig. 5).
This suppression persisted 16 h (Fig. 5) and 24 h (Fig. 2B)
after treatment. In contrast, low concentrations of LPS that suppress
CYP2B1 mRNA within 12 h (Fig. 3) failed to suppress CYP2B1 protein
or PROD activity (Fig. 5) at 8 h and, in agreement with the
induction of CYP2B1 mRNA at 6 h (Fig. 3), actually produced a
small induction of CYP2B1 protein at 8 h (Fig. 5).
|
|
in rat hepatocytes (Fig.
7). Furthermore, in agreement with our
experiments using NOS inhibitors, LY83583 blocked the suppression of
CYP2B1 protein caused by 24 h of LPS treatment (Fig. 7). Like LPS,
IL-1 suppressed CYP2B1 protein in hepatocytes, and this effect was also
blocked by LY83583 (Fig. 7).
|
|
Effect of NO Donors.
SNAP and GSNO each release reactive
nitrogen species in aqueous solution. GSNO forms mainly nitrosonium
ion, a nitrosylating species, whereas NO and peroxynitrite (a nitrating
species) are both formed from SNAP (Patel et al., 1999
). Either SNAP or
GSNO added to hepatocyte cultures were able to mimic the suppression of
CYP2B1 protein caused by LPS or IL-1 (Fig. 8B). The effect was not
correlated with the amount of NOx that could be measured in the medium:
GSNO produced suppression at a concentration that did not significantly
increase detectable NOx, whereas SNAP produced CYP2B1 protein
suppression only at a concentration that also resulted in high levels
of NOx in the media (Fig. 8).
NO-Independent Suppression of CYP2B1 Protein at Later Time
Points.
Because suppression of CYP2B1 mRNA by LPS must ultimately
lead to suppression of CYP2B1 protein, and because suppression of CYP2B1 mRNA is not prevented by NMA or AG, we hypothesized that NOS
inhibitors would be ineffective in blocking the down-regulation of
CYP2B1 protein at later time points. As shown in Fig.
9, this proved to be correct. LPS
treatment caused a suppression of CYP2B1 protein to 20% of control
levels, and this was unaffected by NMA, which effectively blocked NOx
production.
|
| |
Discussion |
|---|
|
|
|---|
The results of this study clearly indicate that CYP2B1 expression in hepatocytes is down-regulated by LPS via two different mechanisms: one occurs at high concentrations of LPS and is NO-dependent and the other occurs at lower LPS concentrations and is NO-independent. Several lines of evidence argue for an NO-dependent suppression of CYP2B1 protein at high concentrations of LPS and at early (24 h or less) time points in the response: CYP2B1 protein levels and catalytic activities are reduced after only 6 to 8 h of LPS treatment (Figs. 5 and 6), at a time when CYP2B1 mRNA has not yet decreased (Fig. 4); the concentration dependence of CYP2B1 protein suppression is very similar to that of NOS induction (Fig. 2); CYP2B1 suppression is reversed by two classes of compounds that block NO production by different mechanisms (Figs. 6,7); blockade of CYP2B1 suppression by the competitive NOS inhibitor is reversed by the NOS substrate arginine (Fig. 8); and CYP2B1 down-regulation is mimicked by NO donors (Fig. 8). Two major findings argue against a role of NO in the suppression of CYP2B1 mRNA by LPS treatment: LPS suppression of CYP2B1 mRNA is several orders of magnitude more potent than the induction of NO production or the suppression of CYP2B1 protein (Fig. 2) and CYP2B1 mRNA suppression by LPS is not inhibited by concentrations of NOS inhibitors that block NO production in the cultures (Fig. 4). The LPS-evoked decline in CYP2B1 mRNA could be caused either by transcriptional suppression or stimulated mRNA degradation; more work is needed to distinguish between these possibilities.
The rapid NO-dependent suppression of CYP2B1 suppression that occurs at
high concentrations of LPS is highly suggestive of an increase in
CYP2B1 protein degradation. Estimates of CYP2B1 protein half-life from
in vitro (Roberts, 1997
) and in vivo experiments (Shiraki and
Guengerich, 1984
) each give a value of about 30 h. Thus,
suppression of CYP2B1 mRNA clearly cannot explain the rapid decline in
CYP2B1 protein observed after LPS stimulation. When CYP2B1 protein is
incubated with peroxynitrite in vitro, an average of two tyrosines per
CYP2B1 molecule are nitrated (Roberts et al., 1998
), and this nitration
is correlated with a decline in CYP2B1 catalytic activity. Whether
nitration of these tyrosines is causative for the observed inhibition,
or indeed for the decrease in CYP2B1 protein levels in the present
study, remains to be determined. It is known that protein modification
by NO-derived species can result in accelerated protein degradation:
e.g., iron-regulatory protein-2 is targeted for ubiquitin-dependent
proteasomal degradation after S-nitrosylation (Kim and
Ponka, 1999
). Interestingly, peroxynitrite-dependent nitration of
CYP8A1 occurs in rat mesangial cells treated with IL-1 (Zou et al.,
1998
), concomitant with loss of catalytic activity. However, this is
apparently not associated with a loss of the CYP8A1 protein in these cells.
It is interesting that GSNO, a nitrosonium ion donor that mainly
results in protein nitrosylation (Patel et al., 1999
) achieves its
effect on CYP2B1 in the absence of a detectable increase in NOx in the
medium. This suggests that the effect of GSNO may be caused by direct
reaction of GSNO with thiols on CYP2B1. SNAP is an NO donor that can
result in peroxynitrite formation in the presence of superoxide anions.
SNAP caused CYP2B1 suppression only at high concentrations when there
were detectable levels of NOx in the medium, which is consistent with a
requirement of high levels of NO to form peroxynitrite. Peroxynitrite,
or species derived from it, in addition to protein nitration, can also
cause protein oxidation and thiol nitrosylation (Patel et al., 1999
). Whether SNAP causes CYP2B1 suppression via nitration, nitrosylation or
oxidation remains to be determined.
Because CYP2B1 protein synthesis is obviously dependent on the level of CYP2B1 mRNA, it is germane to ask why the NO-independent down-regulation of CYP2B1 mRNA does not lead to an NO-independent suppression of CYP2B1 protein at 24 h. In our proposed model, the long half-life of the CYP2B1 protein, coupled with a 6 to 12 h lag before CYP2B1 mRNA suppression occurs (Fig. 4), means that the decrease in mRNA level has little impact on CYP2B1 protein levels up to 24 h after treatment. However, when LPS treatment (and suppression of CYP2B1 mRNA) is prolonged for 48 h, inhibition of CYP2B1 protein degradation by preventing NO production can no longer prevent a decrease in CYP2B1 protein because by this time CYP2B1 synthesis is inhibited because of the decrease in mRNA template. This was confirmed by the experiment in Fig. 9, in which NMA could not prevent CYP2B1 protein suppression after 48 h treatment with LPS.
Recently, Milosevic et al. reported that LPS in the presence of
interferon-
stimulated the suppression of CYP2B1 mRNA and protein in
PB-treated hepatocytes, but only if they were cocultured with Kupffer
cells (Milosevic et al., 1999
). This down-regulation of both CYP2B1
mRNA and protein occurred at 10 ng/ml LPS, and was completely dependent
on TNF
production by the Kupffer cells. Inhibition of NOS activity
with the NOS2-specific inhibitor
L-N6-(1-iminoethyl)-lysine
did not prevent either LPS- or TNF
-evoked suppression of PROD
activity in this system. These findings are in general agreement with
our conclusion that at low concentrations of LPS, NO-independent
mechanisms act to suppress CYP2B1 expression, primarily at the
pretranslational level. The fact that we observed suppression of CYP2B1
mRNA at low concentrations of LPS in the absence of added Kupffer cells
might be related to the presence of Kupffer cell contamination in our
cultures. However, our hepatocyte isolation procedure yields Kupffer
cell contamination of less than 0.5% (Sewer and Morgan, 1997
), similar
to that reported by Milosevic et al. (1999)
. The apparent lack of a
requirement for Kupffer cells in our system could be because our cells
were cultured on Matrigel, which confers a highly differentiated
phenotype on rat hepatocytes (Schuetz et al., 1988
). Hepatocytes have
recently been shown to express CD14, the LPS receptor (Liu et al.,
1998
); thus, LPS can regulate hepatocyte gene expression in the absence of Kupffer cells (Saad et al., 1995
). It may be that CD14-regulated pathways are more active in cells cultured on Matrigel.
Our finding that CYP2B1 protein suppression by high concentrations of
LPS (or by IL-1) is blocked by NOS inhibition is in accord with the
report by Carlson and Billings (1996)
, who observed a relatively modest
decline in CYP2B1 protein levels (33-60% of control) in short-term
cultures of hepatocytes stimulated for 24 h with a cytokine
combination or with IL-1 or TNF
. The relatively high concentrations
of LPS necessary to induce NO production and suppress CYP2B1 by the
NO-dependent mechanism (0.1 µg/ml and above) are relevant to
physiological or pathophysiological concentrations: for example,
endotoxin levels from 30 to 300 ng/ml can be detected in the blood of
children with bacteremia (Scheifele et al., 1981
). It should also be
borne in mind that CD14-dependent responses to LPS are potentiated by
LPS binding to soluble LPS binding protein (Ulevitch and Tobias, 1995
).
Thus, in the presence of this physiological partner (not available to
us), responses of hepatocytes to LPS will be potentiated.
In conclusion, the identification of two different mechanisms (one NO-dependent and one NO-independent) by which LPS can cause suppression of CYP2B1 protein and activity in hepatocytes may provide an explanation for some of the apparently contradictory reports regarding the role of NO in P450 down-regulation by inflammatory mediators. It is possible or likely that other P450 enzymes will be down-regulated by both NO-dependent and -independent mechanisms as well.
| |
Footnotes |
|---|
Received October 12, 2000; Accepted April 9, 2001
This work was supported by Grants GM53093 (E.T.M.), ES03619 (J.R.H.) and ES06676 (University of Texas Medical Branch Center Grant) from the National Institutes of Health.
Edward T. Morgan, Ph.D., Department of Pharmacology, Emory University, 1510 Clifton Road, Atlanta, GA 30322. E-mail: etmorga{at}emory.edu
| |
Abbreviations |
|---|
P450, cytochrome P450;
NOS, nitric-oxide
synthase;
LPS, bacterial lipopolysaccharide;
IL, interleukin;
PB, phenobarbital;
TNF, tumor necrosis factor;
NMA, N
-monomethyl-L-arginine;
AG, aminoguanidine;
GSNO, S-nitrosoglutathione;
SNAP, S-nitroso-N-acetylpenicillamine;
SSC, standard saline citrate;
PROD, pentoxyresorufin
O-dealkylase;
NOx, nitrate + nitrite.
| |
References |
|---|
|
|
|---|
mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes.
Eur J Biochem
229:
349-355[Medline].
and endotoxin in primary rat hepatocytes.
Biochem Pharmacol
54:
729-737[Medline].This article has been cited by other articles:
![]() |
E. T. Morgan, K. B. Goralski, M. Piquette-Miller, K. W. Renton, G. R. Robertson, M. R. Chaluvadi, K. A. Charles, S. J. Clarke, M. Kacevska, C. Liddle, et al. Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer Drug Metab. Dispos., February 1, 2008; 36(2): 205 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-M. Lee, B.-Y. Kim, L. Li, and E. T. Morgan Nitric Oxide-dependent Proteasomal Degradation of Cytochrome P450 2B Proteins J. Biol. Chem., January 11, 2008; 283(2): 889 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Kourylko, C. Fradette, M. Arcand, and P. du Souich MODULATION OF CYP1A2 AND CYP3A6 CATALYTIC ACTIVITIES BY SERUM FROM RABBITS WITH A TURPENTINE-INDUCED INFLAMMATORY REACTION AND INTERLEUKIN 6 Drug Metab. Dispos., January 1, 2006; 34(1): 27 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vuppugalla and R. Mehvar SHORT-TERM INHIBITORY EFFECTS OF NITRIC OXIDE ON CYTOCHROME P450-MEDIATED DRUG METABOLISM: TIME DEPENDENCY AND REVERSIBILITY PROFILES IN ISOLATED PERFUSED RAT LIVERS Drug Metab. Dispos., December 1, 2004; 32(12): 1446 - 1454. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yaghi, J. R. Bend, C. D. Webb, D. C. Zeldin, S. Weicker, S. Mehta, and D. G. McCormack Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1260 - L1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Riddick, C. Lee, A. Bhathena, Y. E. Timsit, P.-Y. Cheng, E. T. Morgan, R. A. Prough, S. L. Ripp, K. K. M. Miller, A. Jahan, et al. TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS Drug Metab. Dispos., April 1, 2004; 32(4): 367 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Morgan, V. Ullrich, A. Daiber, P. Schmidt, N. Takaya, H. Shoun, J. C. McGiff, A. Oyekan, C. J. Hanke, W. B. Campbell, et al. Cytochromes P450 and Flavin Monooxygenases---Targets and Sources of Nitric Oxide Drug Metab. Dispos., November 1, 2001; 29(11): 1366 - 1376. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||